Search results
Results from the WOW.Com Content Network
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [57] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [22]
This page was last edited on 28 September 2024, at 13:01 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The WHO recommendations on which medications should or should not be used to treat Covid-19 are continuously updated. As of July 2022, WHO strongly recommended for non-severe cases nirmatrelvir and ritonavir , and recommended conditionally Molnupiravir , Sotrovimab and Remdesivir .
Dr. Jill Weatherhead, an assistant professor of infectious diseases and tropical medicine at Baylor College of Medicine in Houston, points out that the CDC case reports show that doctors have ...
On 18 March, the WHO launched the Solidarity Trial, an international clinical trial to find an effective treatment for coronavirus disease. [48] [49] [50] On 19 March, the WHO Director-General reported that China had reported no new domestic cases and stated that the WHO was working to ensure the supply chain for protective equipment and tests ...
A new COVID-19 subvariant, known as XBB.1.16 but often called "Arcturus," has progressively become more viral here in the United States, accounting for 10% of infections through late April.
In March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of data on regdanvimab. [10] [11] In October 2021, the EMA started evaluating an application for marketing authorization for the monoclonal antibody regdanvimab (Regkirona) to treat adults with COVID-19 who do not require supplemental oxygen therapy and who ...